Active ingredientIdelalisibCat. No. P-I018-001CAS 870281-82-6Family · Pharmaceutical analytical standards
Idelalisib
An oral inhibitor of PI3K delta, an enzyme found in normal and malignant B lymphocytes. Approved in the United States in July 2014, it was the first drug of the PI3K inhibitor class; it is used mainly in chronic lymphocytic leukaemia. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It works on two fronts: it switches off B-cell receptor signals and blocks the chemical calls, such as those of the CXCR4 and CXCR5 receptors, that guide these cells to their hideouts in the lymph nodes and bone marrow.
Go to the active ingredient →Active ingredientIdelalisibCat. No. P-I018-001CAS 870281-82-6
MetaboliteIdelalisib MetaboliteCat. No. P-I018-002
Isotopically labelledIdelalisib Metabolite-d5Cat. No. P-I018-004
Isotopically labelledIdelalisib-d5Cat. No. P-I018-005CAS 1830330-31-8
NitrosamineN-Nitroso IdelalisibCat. No. P-I018-006
ImpurityIdelalisib Impurity 1Cat. No. P-I018-007CAS 2044710-26-9
ImpurityIdelalisib INTCat. No. P-I018-008CAS 870281-86-0
Impurity2-amino-6-fluoro-N-phenylbenzamideCat. No. P-I018-009CAS 1417456-04-2
ImpurityIdelalisib Impurity 2Cat. No. P-I018-010
ImpurityIdelalisib Impurity 3Cat. No. P-I018-011
ImpurityIdelalisib Impurity 4Cat. No. P-I018-012
ImpurityIdelalisib Impurity 5Cat. No. P-I018-013
ImpurityIdelalisib Impurity 6Cat. No. P-I018-014No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.